Quantel Medical has completed its acquisition of Ellex, including the company’s laser and ultrasound technology solutions (with the exception of 2RT and iTrack), via the financial holding company Lumibird Medical. The purchase includes the Ellex brand name, its research and development and production site based in Adelaide and its subsidiaries based in Australia, Japan, the United States, France, and Germany.

The coming together of these 2 companies represents a milestone in their history. Quantel Medical and Ellex have a shared heritage in the development of cutting-edge technologies for the diagnosis and treatment of the leading causes of blindness worldwide: glaucoma, cataracts, age-related macular degeneration, and diabetic retinopathy.

The combination of Quantel Medical and Ellex offers major potential for growth and value creation through various synergies, including the sharing of research and development capacity and production sites, and the strengthening of their clinical work to meet the current and future needs of ophthalmologists.

Quantel Medical and Ellex note that they have complementary strengths, in particular their product positioning, experience, and knowledge of the ophthalmology market. Bringing together the product portfolios of both companies will enable them to better meet the needs of health care professionals, in both the applications and positioning of their ranges.

In a related move, Ellex has spun off its iTrack MIGS portfolio into a dedicated glaucoma company, known as Nova Eye Medical and has acquired the Molteno3 glaucoma drainage device business from Molteno Ophthalmic Limited.